
    
      This study consists of three periods:

        1. Screening Period up to 28 days

        2. Treatment Period of 16 weeks

        3. A Follow-up period of 4 weeks.

      A total of up to approximately 100 patients will be enrolled to receive roxadustat in an
      open-label manner.
    
  